UY35685A - Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso - Google Patents

Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso

Info

Publication number
UY35685A
UY35685A UY0001035685A UY35685A UY35685A UY 35685 A UY35685 A UY 35685A UY 0001035685 A UY0001035685 A UY 0001035685A UY 35685 A UY35685 A UY 35685A UY 35685 A UY35685 A UY 35685A
Authority
UY
Uruguay
Prior art keywords
beta
tiazine
methods
secretase inhibitors
compounds
Prior art date
Application number
UY0001035685A
Other languages
English (en)
Inventor
Richard T Lewis
Brown James
Guzman-Perez Angel
Hua Zihao
Philip R Olivieri
Romero Karina
Jennifer R Allen
Liu Qingyian
White Ryan
Schenkel Laurie
Stellwagen John
Judd Ted
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY35685A publication Critical patent/UY35685A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de compuestos útiles para la modulación de la actividad de la enzima beta-secretasa (BACE). Los compuestos tienen una Fórmula general I: donde las variables A4, A5, A6, A8, R1, R2, R3, R7, y n de Fórmula I, independientemente, se definen en la presente. La invención también proporciona composiciones farmacéuticas que comprenden los compuestos, y usos correspondientes de los compuestos y composiciones para el tratamiento de trastornos y/o afecciones relacionados con la formación y depósito de placa Abeta que resulta de la actividad biológica de BACE.
UY0001035685A 2013-07-30 2014-07-30 Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso UY35685A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361859923P 2013-07-30 2013-07-30

Publications (1)

Publication Number Publication Date
UY35685A true UY35685A (es) 2015-01-30

Family

ID=51301366

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035685A UY35685A (es) 2013-07-30 2014-07-30 Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso

Country Status (5)

Country Link
US (2) US9096615B2 (es)
AR (1) AR097157A1 (es)
TW (1) TW201602116A (es)
UY (1) UY35685A (es)
WO (1) WO2015017407A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
JP2017088776A (ja) * 2015-11-13 2017-05-25 信越化学工業株式会社 付加硬化型シリコーン樹脂組成物、該組成物の製造方法、及び光学半導体装置
US10689401B2 (en) * 2016-02-11 2020-06-23 Merck Sharp & Dohme Corp. C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
US20210261561A1 (en) * 2018-04-23 2021-08-26 Shionogi & Co., Ltd. Bicyclic heterocycle derivatives having selective bace1 inhibitory activity
US11629154B2 (en) 2018-04-27 2023-04-18 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
SG113454A1 (en) 1998-09-24 2005-08-29 Upjohn Co Alzheimer's disease secretase
WO2006081178A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JPWO2011058763A1 (ja) 2009-11-13 2013-03-28 塩野義製薬株式会社 アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体
CN102834384A (zh) 2009-12-11 2012-12-19 盐野义制药株式会社 *嗪衍生物
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
KR20140010031A (ko) 2011-01-13 2014-01-23 노파르티스 아게 대사 장애의 치료를 위한 ｂａｃｅ-2 억제제
US9067924B2 (en) 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012139425A1 (en) 2011-04-13 2012-10-18 Schering Corporation 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
JP2014524472A (ja) * 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
WO2013148851A1 (en) 2012-03-27 2013-10-03 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
CN104334554B (zh) 2012-05-24 2017-10-31 霍夫曼-拉罗奇有限公司 作为bace1抑制剂的5‑氨基[1，4]噻嗪类
WO2013182638A1 (en) 2012-06-08 2013-12-12 H. Lundbeck A/S 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
EP2934149B1 (en) 2012-12-20 2019-02-06 Merck Sharp & Dohme Corp. C6-azaspiro iminothiadiazine dioxides as bace inhibitors
US9580396B2 (en) 2012-12-21 2017-02-28 Merck Sharp & Dohme Corp. C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
WO2014150331A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
US9428476B2 (en) 2013-03-15 2016-08-30 Merck Sharp & Dohme Corp. S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use

Also Published As

Publication number Publication date
US20150038497A1 (en) 2015-02-05
AR097157A1 (es) 2016-02-24
WO2015017407A1 (en) 2015-02-05
US9096615B2 (en) 2015-08-04
TW201602116A (zh) 2016-01-16
US20150252059A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
UY35361A (es) COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
CR20150371A (es) Inhibidores de prmt5 y sus usos
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
ECSP16074478A (es) Compuestos novedosos
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211207